Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER-2/neu-overexpressing human breast cancer cells to docetaxel (taxotere)

Breast Cancer Research and Treatment

Volumn 84, Issue 2, 2004, Pages 183-195

  Menendez, Javier A ^a,b   Lupu, Ruth ^a,b   Colomer, Ramon ^c  

^a Evanston NW Research Institute ^*  (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Breast cancer; Cerulenin; Chemotherapy; Docetaxel; Fatty acid synthase; HER 2 neu; Taxotere

Indexed keywords

CERULENIN; DOCETAXEL; FATTY ACID SYNTHASE; MYCOTOXIN; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL; CATALYSIS; CELL INTERACTION; CHEMOSENSITIVITY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID SYNTHESIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPERACTIVITY; LIPOGENESIS; ONCOGENE NEU; PRIORITY JOURNAL;

ANTIBIOTICS, ANTIFUNGAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CERULENIN; DRUG RESISTANCE, NEOPLASM; FATTY ACID SYNTHETASE COMPLEX; FEMALE; GENES, ERBB-2; HUMANS; TAXOIDS; TRANSFECTION;

EID: 1642296150     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000018409.59448.60     Document Type: Article

References (74)

1. Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM: Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 63: 132-139, 2003
2. Kuhajda FP, Piantadosi S, Pasternack GR: Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N Engl J Med 321: 636-641, 1989
3. Corrigan C, Martin AW, Lear SC, Kuhns S, Kuhajda FP, Pasternack GR: Prognostic value of the immunohistochemical demonstration of haptoglobin-related protein in breast cancer. Am J Clin Pathol 96: 406, 1991
4. Jensen V, Holm-Nielsen P, Melsen F: OA-519 expression in node negative breast cancer Breast Cancer Res Treat 27: 1-2, 1993
5. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, Pasternack GR: Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 91: 6379-6383, 1994
6. Alo PL, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U: Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77: 474-482, 1996
7. Alo PL, Visca P, Trombetta G, Mangoni A, Lenti L, Monaco S, Botti C, Serpieri DE, Di Tondo U: Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori 85: 35-40, 1999
8. Kuhajda FP: Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology Nutrition 16: 202-208, 2000
9. Weiss L, Hoffman GE, Schreiber R, Andres H, Fuchs E, Korber E, Kolb HJ: Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty acid synthase. Biol Chem Hoppe Seyler 267: 905-912, 1986
10. Ookhtens M, Kannan R, Lyon I, Baker N: Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am J Physiol 247: R146-R153, 1984
11. Pizer ES, Wood FD, Pasternack GR, Kuhajda FP: Fatty acid synthase (FAS): a target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells. Cancer Res 56: 745-751, 1996
12. Vance D, Goldberg I, Mitsuhashi O, Bloch K: Inhibition of fatty acid synthethases by the antibiotic cerulenin. Biochem Biophys Res Commun 48: 549-565, 1972
13. Omura S: The antibiotic cerulenin: a novel tool for biochemistry as an inhibitor of fatty acid synthesis. Bact Rev 40: 681-697, 1976
14. Christie WW, Hunter ML, Clegg RA: The effects of cerulenin on lipid metabolism in vitro in cellular preparation from the rat. Biochim Biophys Acta 666: 284-290, 1981
15. Funabashi H, Kawaguchi A, Tomoda H, Omura S, Okuda S, Iwasaki S: Binding site of cerulenin in fatty acid synthetase. J Biochem 105: 751-755, 1989
16. Moche M, Schneider G, Edwards P, Dehesh K, Lindqvist Y: Structure of the complex between the antibiotic cerulenin and its target, β-ketoacyl carrier protein synthase. J Biol Chem 274: 6031-6034, 1999
17. Pizer ES, Jackisch C, Wood FD, Pasternack GR, Davidson NE, Kuhajda FP: Inhibition of fatty acid synthase induces programmed cell death in human breast cancer cells. Cancer Res 56: 2745-2747, 1996
18. Pizer ES, Chrest FJ, DiGiuseppe JA, Han WF: Pharmacological inhibition of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res 58: 4611-4615, 1998
19. Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot GL, Townsend CA, Kuhajda FP: Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 60: 213-218, 2000
20. Li JN, Gorospe M, Chrest FJ, Kumaravel TS, Evans MK, Han WF, Pizer ES: Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res 61: 1493-1499, 2001
21. Pizer ES, Wood FD, Heine HS, Romantsev FE, Pasternack GR, Kuhajda FP: Inhibition of fatty acid synthase delays disease progression in a xenograft model of ovarian cancer. Cancer Res 56: 1189-1193, 1996
22. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA: Synthesis and anti-tumor activity of a novel inhibitor of fatty acid synthase. Proc Natl Acad Sci USA 97: 3450-3454, 2000
23. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA: erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237: 178-182, 1987
24. Pierce JH, Arnstein P, DiMarco E, Artrip J, Kraus MH, Lonardo F, Di Fiore PP, Aaronson SA: Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene 6: 1189-1194, 1991
25. Yu D, Hamada J, Zhang H, Nicolson GL, Hung MC: Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. Oncogene 7: 2263-2270, 1992
26. Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL, Hung MC: c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 54: 3260-3266, 1994
27. Yu D, Hung M-C: Role of erbB2 in breast cancer chemosensitivity. BioEssays 22: 673-680, 2000
28. Kim R, Tanabe K, Uchida Y, Osaki A, Toge T: The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review). Oncol Rep 9: 3-9, 2002
29. Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC: Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 13: 1359-1365, 1996
30. Ueno NT, Yu D, Hung MC: Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene 15: 953-960, 1997
31. mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 16: 2087-2094, 1998
32. Ciardiello F, Caputo R, Pomatico G, De Laurentiis M, De Placido S, Bianco AR, Tortora G: Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. Int J Cancer 85: 710-715, 2000
33. Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, Massuti B, Cortes-Funes H, Lloveras B: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6: 2356-2362, 2000
34. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987
35. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989
36. Loftus TM, Jaworsky DE, Frehywot GL, Townsend CA, Ronnett GV, Lane MD, Kuhajda FP: Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 288: 2379-2381, 2000
37. Thupari JN, Landree LE, Ronnett GV, Kuhajda FP: C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci USA 99: 9498-9502, 2002
38. Wortman MD, Clegg DJ, D'Alessio D, Woods SC, Seeley RJ: C75 inhibits food intake by increasing CNS glucose metabolism. Nat Med 9: 483-485, 2003
39. Gao S, Lane MD: Effect of the anorectic fatty acid synthase inhibitor C75 on neuronal activity in the hypothalamus and brainstem. Proc Natl Acad Sci USA 100: 5628-5633, 2003
40. Moelling K, Schulze T, Knoop MT, Kay J, Jupp R, Nicolaou G, Pearl LH: In vitro inhibition of HIV-1 proteinase by cerulenin. FEBS Lett 261: 373-377, 1990
41. Perez L, Carrasco L: Cerulenin, an inhibitor of lipid synthesis, blocks vesicular stomatitis virus RNA replication. FEBS Lett 280: 129-133, 1991
42. Simon SM, Aderem A: Myristoylation of proteins in the yeast secretory pathway. J Biol Chem. 267: 3922-3931, 1992
43. Ringel I, Horwitz SB: Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288-291, 1991
44. Diaz JF, Andreu JM: Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 32: 2747-2755, 1993
45. Verweij J, Clavel M, Chevalier B: Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 5: 495-505, 1994
46. Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, Holmes FA, Rahman Z, Schottstaedt MW, Erban JK, Esparza-Guerra L, Earhart RH, Hortobagyi GN, Burris HA 3rd: A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16: 3362-3368, 1998
47. Burris HA 3rd: Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin). Semin Oncol 27(2 Suppl 3): 19-23, 2000
48. Burris HA 3rd: Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol 28(1 Suppl 3): 38-44, 2001
49. Esteva FJ: The current status of docetaxel for metastatic breast cancer. Oncology 16(6 Suppl 6): 17-26, 2002
50. Dils R, Carey EM: Fatty acid synthase from rabbit mammary gland. Methods Enzymol 35: 74-83, 1975
51. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-4289, 1992
52. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26(4 Suppl 12): 60-70, 1999
53. Klapper LN, Waterman H, Sela M, Yarden Y: Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 60: 3384-3388, 2000
54. Yarden Y: Biology of HER2 and its importance in breast cancer. Oncology 61(Suppl. 2): 1-13, 2001
55. Baselga J, Albanell J, Molina MA, Arribas J: Mechanism of action of trastuzumab and scientific update. Semin Oncol 28(5 Suppl 16): 4-11, 2001
56. Albanell J, Codony J, Rovira A, Mellado B, Gascon P: Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 532: 253-268, 2003
57. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241-2251, 1999
58. Pegram MD, Lopez A, Konecny G, Slamon DJ: Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 27(6 Suppl 11): 21-25, 2000
59. Slamon D, Pegram M: Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28(1 Suppl 3): 13-19, 2001
60. Chou T-C, Talalay, P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984
61. Berenbaum MC: What is synergy? Pharmacol Rev 41: 93-141, 1989
62. Nugent A, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ: Measurement of erbB-2 oncoprotein in human breast cancers by ELISA. Biochem Soc Trans 20: 82S, 1992
63. Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MC: E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 6: 250-259, 2000
64. Menendez JA, Ropero S, Vazquez-Martin A, Cortes-Funes H, Lupu R, Colomer R: Trastuzumab and cerulenin synergistically inhibit breast cancer cell growth: interaction of HER-2/neu and fatty acid synthase signaling pathways. Proc Am Assoc Cancer Res Abstract 2989, 2002
65. Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R: A molecular cross-communication between Heregulin/HER2 and fatty acid synthase in breast cancer cells. Proc Am Assoc Cancer Res Abstract 6207, 2003
66. Xing X, Wang SC, Xia W, Zou Y, Shao R, Kwong KY, Yu Z, Zhang S, Miller S, Huang L, Hung MC: The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nature Med 6: 189-195, 2000
67. Swinnen JV, Van Veldhoven PP, Timmermans L, De Schrijver E, Brusselmans K, Vanderhoydonc F, Van de Sande T, Heemers H, Heyns W, Verhoeven G: Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun 302: 898-903, 2003
68. Draber P, Draberova L: Lipid rafts in mast cell signaling. Mol Immunol 38: 1247-1252, 2002
69. Nagy P, Vereb G, Sebestyen Z, Horvath G, Lockett SJ, Damjanovich S, Park JW, Jovin TM, Szollosi J: Lipid rafts and the local density of ErbB proteins influence the biological role of homo-and heteroassociations of ErbB2. J Cell Sci 115: 4251-4262, 2002
70. Xie Y, Hung MC: Nuclear localization of p185neu tyrosine kinase and its association with transcriptional transactivation. Biochem Biophys Res Commun 203: 1589-1598, 1994
71. Kip1, BRCA1 and NF-κB. Int J Oncol (in press)
72. Moscow JA, Cowan KH: Multidrug resistance. J Natl Cancer Inst 80: 14-20, 1988
73. Nooter K, Herweijer H: Multidrug resistance (mdr) genes in human cancer. Br J Cancer 63: 663-669, 1991
74. Vazquez-Martin A, Menendez JA, Ropero S, Montero S, Cortes-Funes H, Colomer R: Anthracycline resistance on breast cancer cells is reversed by inhibition of fatty acid synthase. Proc Am Assoc Cancer Res. Abstract 4709, 2002